Ironwood said it believes VectivBio’s once-weekly GLP-2 analog apraglutide is differentiated from Takeda’s once-daily Gattex in short bowel syndrome and could generate $1bn in peak sales.

Deal Snapshot: Using antibodies against an undisclosed target discovered and engineered by Innate, Takeda plans to investigate the potential of antibody-drug conjugates in celiac disease

Japanese firm exercises option after promising Phase I results in disorder with no approved drugs, in deal that builds out its celiac pipeline.

Deal follows 2013 pact between Ambrx and NovoCodex parent Zhejiang Medicine for HER2-positive-directed ADC. Astellas teams with Pandion on pancreatic cancer and Takeda with MD Anderson on CAR NK therapies.